AACR: T-DM1 Most Effective in Breast Cancer Patients With High HER2 Expression

Researchers participating in the phase III EMILIA trial have identified tumor biomarkers that can identify patients that are more likely to benefit from T-DM1. In the trial, women whose tumors had higher HER2 expression were most likely to benefit from the therapy.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news